KR20050044318A - 특정 투여량의 폰다파리눅스 소듐의 ａｃｓ 치료를 위한용도 - Google Patents
특정 투여량의 폰다파리눅스 소듐의 ａｃｓ 치료를 위한용도 Download PDFInfo
- Publication number
- KR20050044318A KR20050044318A KR1020047004779A KR20047004779A KR20050044318A KR 20050044318 A KR20050044318 A KR 20050044318A KR 1020047004779 A KR1020047004779 A KR 1020047004779A KR 20047004779 A KR20047004779 A KR 20047004779A KR 20050044318 A KR20050044318 A KR 20050044318A
- Authority
- KR
- South Korea
- Prior art keywords
- sulfo
- acs
- treatment
- sulfoamino
- deoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 229960003661 fondaparinux sodium Drugs 0.000 title 1
- XEKSTYNIJLDDAZ-JASSWCPGSA-F fondaparinux sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C(O)=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-F 0.000 title 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 150000002972 pentoses Chemical class 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 description 20
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 20
- 208000034158 bleeding Diseases 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- 230000000740 bleeding effect Effects 0.000 description 19
- 229910052708 sodium Inorganic materials 0.000 description 19
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 15
- 229960000610 enoxaparin Drugs 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 206010000891 acute myocardial infarction Diseases 0.000 description 6
- 239000003055 low molecular weight heparin Substances 0.000 description 5
- 229940127215 low-molecular weight heparin Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010002388 Angina unstable Diseases 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 208000007814 Unstable Angina Diseases 0.000 description 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 108010074860 Factor Xa Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 108010029144 Factor IIa Proteins 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010056457 Intra-abdominal haematoma Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000011218 binary composite Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- -1 pentose sugars Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01204323.8 | 2001-11-13 | ||
| EP01204323 | 2001-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050044318A true KR20050044318A (ko) | 2005-05-12 |
Family
ID=8181220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047004779A Ceased KR20050044318A (ko) | 2001-11-13 | 2002-11-07 | 특정 투여량의 폰다파리눅스 소듐의 ａｃｓ 치료를 위한용도 |
Country Status (36)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090075910A1 (en) * | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched fondaparinux |
| EP3271405A1 (en) * | 2015-03-20 | 2018-01-24 | Aarhus Universitet | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders |
| US10688249B2 (en) * | 2015-06-11 | 2020-06-23 | Virchow Biotech Pvt. Ltd. | Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same |
| CN107595769A (zh) * | 2017-10-23 | 2018-01-19 | 上海博悦生物科技有限公司 | 一种磺达肝癸钠注射液组合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2662442A1 (fr) * | 1990-05-23 | 1991-11-29 | Midy Spa | Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant. |
| CA2199642C (en) * | 1997-03-10 | 2001-05-08 | Roger Cariou | Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin |
| FR2764511B1 (fr) * | 1997-06-13 | 2000-09-08 | Sanofi Sa | Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire |
| US20040087543A1 (en) * | 2002-04-25 | 2004-05-06 | Zachary Shriver | Methods and products for mucosal delivery |
-
2002
- 2002-07-11 UA UA2004032373A patent/UA80399C2/uk unknown
- 2002-11-07 ES ES02787601T patent/ES2287343T3/es not_active Expired - Lifetime
- 2002-11-07 HR HR20040303A patent/HRP20040303B1/xx not_active IP Right Cessation
- 2002-11-07 AT AT02787601T patent/ATE361753T1/de active
- 2002-11-07 CN CNA028192567A patent/CN1602197A/zh active Pending
- 2002-11-07 KR KR1020047004779A patent/KR20050044318A/ko not_active Ceased
- 2002-11-07 GE GE5516A patent/GEP20074097B/en unknown
- 2002-11-07 ME MEP-2008-11A patent/ME00229B/me unknown
- 2002-11-07 PL PL369027A patent/PL206008B1/pl unknown
- 2002-11-07 DK DK02787601T patent/DK1446131T3/da active
- 2002-11-07 JP JP2003543609A patent/JP4523276B2/ja not_active Expired - Fee Related
- 2002-11-07 MX MXPA04003045A patent/MXPA04003045A/es active IP Right Grant
- 2002-11-07 PT PT02787601T patent/PT1446131E/pt unknown
- 2002-11-07 AU AU2002351915A patent/AU2002351915B2/en not_active Expired
- 2002-11-07 ME MEP-11/08A patent/MEP1108A/xx unknown
- 2002-11-07 EA EA200400382A patent/EA007325B1/ru unknown
- 2002-11-07 US US10/492,102 patent/US20040248848A1/en not_active Abandoned
- 2002-11-07 WO PCT/EP2002/012482 patent/WO2003041722A1/en not_active Ceased
- 2002-11-07 NZ NZ552129A patent/NZ552129A/en not_active IP Right Cessation
- 2002-11-07 RS YUP-267/04A patent/RS50906B/sr unknown
- 2002-11-07 BR BR0212915-9A patent/BR0212915A/pt not_active Application Discontinuation
- 2002-11-07 DE DE60220084T patent/DE60220084T2/de not_active Expired - Lifetime
- 2002-11-07 CA CA002465776A patent/CA2465776A1/en not_active Abandoned
- 2002-11-07 HU HU0401462A patent/HU228959B1/hu unknown
- 2002-11-07 SI SI200230578T patent/SI1446131T1/sl unknown
- 2002-11-07 PE PE2002001086A patent/PE20030740A1/es not_active Application Discontinuation
- 2002-11-07 IL IL16111402A patent/IL161114A0/xx unknown
- 2002-11-07 AP APAP/P/2004/003014A patent/AP1820A/en active
- 2002-11-07 EP EP02787601A patent/EP1446131B1/en not_active Expired - Lifetime
- 2002-11-11 AR ARP020104308A patent/AR037291A1/es unknown
-
2004
- 2004-03-25 IL IL161114A patent/IL161114A/en active IP Right Grant
- 2004-03-29 ZA ZA2004/02464A patent/ZA200402464B/en unknown
- 2004-03-29 IS IS7199A patent/IS2484B/is unknown
- 2004-03-30 NO NO20041320A patent/NO20041320L/no not_active Application Discontinuation
- 2004-03-31 CO CO04030711A patent/CO5580790A2/es not_active Application Discontinuation
- 2004-03-31 EC EC2004005041A patent/ECSP045041A/es unknown
- 2004-03-31 MA MA27602A patent/MA27071A1/fr unknown
-
2007
- 2007-07-30 CY CY20071101000T patent/CY1106765T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK175978B1 (da) | Anvendelse af AICA-ribosid eller AICA-ribotid til fremstilling af et farmaceutisk præparat til behandling af hjerteanfald eller salgtilfælde i patienter, som lider af atherosklerose | |
| Théry et al. | Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. | |
| US4451454A (en) | Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals | |
| JPH072644B2 (ja) | 抗血栓組成物 | |
| KR20050044318A (ko) | 특정 투여량의 폰다파리눅스 소듐의 ａｃｓ 치료를 위한용도 | |
| AU2002351915A1 (en) | Uso of specific dose of fondaparinux sodium for the treatment of ACS | |
| Nesvold et al. | Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction. A dose-finding study | |
| JP2005509007A6 (ja) | Ａｃｓの治療のためのフォンダパリヌックスナトリウムの特定投与量の使用 | |
| HK1070561B (en) | Use of specific dose of fondaparinux sodium for the treatment of acs | |
| Beedkar et al. | Heart failure and the iron deficiency | |
| Sagripanti et al. | Iloprost in the treatment of thrombotic microangiopathy: report of thirteen cases | |
| ES2262971T3 (es) | Idraparinux (sanorg 34006) para el tratamiento y profilaxis secundaria de sucesos tromboembolicos venosos en pacientes con trombosis venosa intensa. | |
| JPS6354690B2 (https=) | ||
| Walenga et al. | Combined thrombin and platelet inhibition treatment for HIT patients | |
| Dalteparin | Thromhoprophylaxis in Hip Fracture Surgery: A Pilot Study Gomparing | |
| Jimenez | Idiopathic migratory thrombophlebitis: Report of 4 cases | |
| Ahrens et al. | THE BENEFITS OF RIVAROXABAN (XARELTO®) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS | |
| HK1072361B (en) | Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20040331 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20051116 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20070821 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20081224 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20090622 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20081224 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |